The product is a generic version of Chiesi USA Inc’s Zyflo CR extended-release tablets in the same strength, it added.
The company has launched Zileuton extended-release tablets in the strength of 600 mg, having received an approval from the United States Food and Drug Administration (USFDA) earlier, Lupin said in a BSE filing.
According to IQVIA MAT June 2020 data, Zileuton extended-release tablets had an annual sales of approximately USD 40 million in the US, Lupinsaid.
The tablets are indicated for the prophylaxis and chronic treatment of asthma in adults and children 12 years of age and older, it added.
Shares of Lupin Ltd closed at Rs957.95per scrip on the BSE, up 0.01 per cent from its previous close.
(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)